In Brief: Grace reviewing NMC options
This article was originally published in The Gray Sheet
Executive SummaryGrace reviewing NMC options: W.R. Grace's newly elected president and CEO Albert Costello tells shareholders at Grace's May 10 annual meeting that the firm is weighing several alternatives for the divestiture of its National Medical Care dialysis unit. Last week, Grace received a $3.5 bil. acquisition offer for NMC from Constantine Hampers, a Grace executive VP and NMC's chairman and CEO ("The Gray Sheet" May 8, p. 14). "We are giving [Hampers'] proposal serious consideration and have retained the services of Merrill Lynch and First Boston to help us evaluate it," Costello told the stockholders in Boca Raton, Florida. Grace's board will "evaluate the Hampers proposal and other alternatives relating to NMC within approximately 30 to 60 days," the company said in a release...
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.